AzTrials
AzTrials

Arthritis, RheumatoidPhase 3NCT00856544

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

A Phase 3 study testing CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 133 sites in 20 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arthritis, Rheumatoid
What is being tested?
CP-690,550
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
795 participants
Where
133 sitesin 20 countries
Study dates
May 2009to Jan 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The patient has a diagnosis of Rheumatoid Arthritis based on the American College of Rheumatology (ACR) 1987 Revised Criteria.
  • The patient has active disease as defined by both >=4 tender or painful joints on motion and >= 4 joints swollen; and either an erythrocyte sedimentation rate (ESR) > 28 mm or a C-reactive protein (CRP) concentration > 7 mg/dL.
  • Patient had an inadequate response to at least one disease modifying antirheumatic drug (traditional or biologic) due to lack of efficacy or toxicity.
  • Patient must remain on at least one background traditional disease modifying antirheumatic drug.
  • No evidence of inadequately treated latent or active infection with Mycobacterium tuberculosis.

Who cannot join

  • Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count <100 x 109/L.
  • History of any other rheumatic autoimmune disease other than Sjogren's syndrome.
  • No malignancy or history of malignancy.
  • History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug.

Trial locations and contacts

133 sites in 20 countries.

133 sites in 20 countries

United States46 sites
  • Pfizer Investigational Site

    Albany, New York, 12206

  • Pfizer Investigational Site

    Asheville, North Carolina, 28801

  • Pfizer Investigational Site

    Austin, Texas, 78705

  • Pfizer Investigational Site

    Bethlehem, Pennsylvania, 18015

  • Pfizer Investigational Site

    Boulder, Colorado, 80304

  • Pfizer Investigational Site

    Charlotte, North Carolina, 28210

  • Pfizer Investigational Site

    Clarksburg, West Virginia, 26301

  • Pfizer Investigational Site

    Dallas, Texas, 75235

  • Pfizer Investigational Site

    Danbury, Connecticut, 06810

  • Pfizer Investigational Site

    Decatur, Georgia, 30033

  • Pfizer Investigational Site

    Denver, Colorado, 80206

  • Pfizer Investigational Site

    Edina, Minnesota, 55435

  • Pfizer Investigational Site

    Evansville, Indiana, 47714

  • Pfizer Investigational Site

    Greenville, South Carolina, 29601

  • Pfizer Investigational Site

    Hamden, Connecticut, 06518

  • Pfizer Investigational Site

    Huntsville, Alabama, 35801

  • Pfizer Investigational Site

    Indianapolis, Indiana, 46227

  • Pfizer Investigational Site

    Jonesboro, Arkansas, 72401

  • Pfizer Investigational Site

    Knoxville, Tennessee, 37909

  • Pfizer Investigational Site

    Leominster, Massachusetts, 01453

  • Pfizer Investigational Site

    Lexington, Kentucky, 40505

  • Pfizer Investigational Site

    Lincoln, Nebraska, 68516

  • Pfizer Investigational Site

    Marietta, Georgia, 30060

  • Pfizer Investigational Site

    Maywood, Illinois, 60153

  • Pfizer Investigational Site

    New Port Richey, Florida, 34652

  • Pfizer Investigational Site

    Oakbrook Terrace, Illinois, 60181

  • Pfizer Investigational Site

    Ocala, Florida, 34474

  • Pfizer Investigational Site

    Orchard Park, New York, 14127

  • Pfizer Investigational Site

    Palo Alto, California, 94304

  • Pfizer Investigational Site

    Plantation, Florida, 33324

  • Pfizer Investigational Site

    Port Richey, Florida, 34668

  • Pfizer Investigational Site

    Rochester, New York, 14618

  • Pfizer Investigational Site

    Rockford, Illinois, 61103-3692

  • Pfizer Investigational Site

    Seattle, Washington, 98133

  • Pfizer Investigational Site

    Springfield, Illinois, 62702

  • Pfizer Investigational Site

    Springfield, Illinois, 62703

  • Pfizer Investigational Site

    Stanford, California, 94305

  • Pfizer Investigational Site

    Tacoma, Washington, 98405-2308

  • Pfizer Investigational Site

    Tacoma, Washington, 98405

  • Pfizer Investigational Site

    Tamarac, Florida, 33321

  • Pfizer Investigational Site

    Tampa, Florida, 33613

  • Pfizer Investigational Site

    Trumbull, Connecticut, 06611

  • Pfizer Investigational Site

    Vernon Hills, Illinois, 60061

  • Pfizer Investigational Site

    Wichita, Kansas, 67203

  • Pfizer Investigational Site

    Worcester, Massachusetts, 01605

  • Pfizer Investigational Site

    Wyomissing, Pennsylvania, 19610

Other trials in United States

China20 sites
  • Pfizer Investigational Site

    Beijing, 100020

  • Pfizer Investigational Site

    Beijing, 100044

  • Pfizer Investigational Site

    Beijing, 100853

  • Pfizer Investigational Site

    Changsha, Hunan, 410008

  • Pfizer Investigational Site

    Chengdu, Sichuan, 610041

  • Pfizer Investigational Site

    Guangzhou, Guangdong, 510260

  • Pfizer Investigational Site

    Guangzhou, Guangdong, 510630

  • Pfizer Investigational Site

    Hangzhou, Zhejiang, 310009

  • Pfizer Investigational Site

    Hefei, Anhui, 230001

  • Pfizer Investigational Site

    Hefei, Anhui, 230022

  • Pfizer Investigational Site

    Jinan, Shandong, 250012

  • Pfizer Investigational Site

    Nanjing, Jiangsu, 210029

  • Pfizer Investigational Site

    Qingdao, Shandong, 266011

  • Pfizer Investigational Site

    Shanghai, 200001

  • Pfizer Investigational Site

    Shanghai, 200003

  • Pfizer Investigational Site

    Shanghai, 200433

  • Pfizer Investigational Site

    Suzhou, Jiangsu, 215006

  • Pfizer Investigational Site

    Tianjin, 300052

  • Pfizer Investigational Site

    Wuhan, Hubei, 430030

  • Pfizer Investigational Site

    Xi’an, Shanxi, 710032

Other trials in China

Australia6 sites
  • Pfizer Investigational Site

    Cairns, Queensland, 4870

  • Pfizer Investigational Site

    Campsie, New South Wales, 2194

  • Pfizer Investigational Site

    Malvern East, Victoria, 3145

  • Pfizer Investigational Site

    Maroochydore, Queensland, 4558

  • Pfizer Investigational Site

    Shenton Park, Western Australia, 6008

  • Pfizer Investigational Site

    Woodville, South Australia, 5011

Other trials in Australia

Germany6 sites
  • Pfizer Investigational Site

    Berlin, 14059

  • Pfizer Investigational Site

    Dresden, 01067

  • Pfizer Investigational Site

    Hamburg, 22081

  • Pfizer Investigational Site

    Leipzig, 04103

  • Pfizer Investigational Site

    Nuremberg, 90429

  • Pfizer Investigational Site

    Rheine, 48431

Other trials in Germany

Slovakia6 sites
  • Pfizer Investigational Site

    Nové Zámky, 94001

  • Pfizer Investigational Site

    Poprad, 058 01

  • Pfizer Investigational Site

    Považská Bystrica, 017 01

  • Pfizer Investigational Site

    Rimavská Sobota, 979 01

  • Pfizer Investigational Site

    Senica, 905 01

  • Pfizer Investigational Site

    Žilina, 010 01

Other trials in Slovakia

Chile5 sites
  • Pfizer Investigational Site

    Providencia, Santiago, RM, 7530206

  • Pfizer Investigational Site

    Santiago, RM, 7510186

  • Pfizer Investigational Site

    Santiago, RM, 8360156

  • Pfizer Investigational Site

    Viña del Mar, Valparaiso, 2570017

  • Pfizer Investigational Site

    Viña del Mar, 2570017

Other trials in Chile

Mexico5 sites
  • Pfizer Investigational Site

    Cuernavaca, Morelos, 62270

  • Pfizer Investigational Site

    Mérida, Yucatán, 97000

  • Pfizer Investigational Site

    México, Querétaro, 76178

  • Pfizer Investigational Site

    Morelia, Michoacán, 58249

  • Pfizer Investigational Site

    Torreón, Coahuila, 27000

Other trials in Mexico

Poland5 sites
  • Pfizer Investigational Site

    Bialystok, 15-337

  • Pfizer Investigational Site

    Bialystok, 15-461

  • Pfizer Investigational Site

    Kościan, 64-000

  • Pfizer Investigational Site

    Poznan, 60-773

  • Pfizer Investigational Site

    Torun, 87-100

Other trials in Poland

Spain5 sites
  • Pfizer Investigational Site

    A Coruña, A Coruña, 15006

  • Pfizer Investigational Site

    Madrid, Madrid, 28046

  • Pfizer Investigational Site

    Málaga, Malaga, 29009

  • Pfizer Investigational Site

    Santiago de Compostela, A Coruña, 15705

  • Pfizer Investigational Site

    Seville, Sevilla, 41013

Other trials in Spain

Malaysia4 sites
  • Pfizer Investigational Site

    Batu Caves, Selangor, 68100

  • Pfizer Investigational Site

    Putrajaya, Kuala Lumpur, 62250

  • Pfizer Investigational Site

    Seremban, Negeri Sembilan, 70300

  • Pfizer Investigational Site

    Subang Jaya, Selangor, 47500

Other trials in Malaysia

United Kingdom4 sites
  • Pfizer Investigational Site

    Cannock, Staffs, WS11 2XY

  • Pfizer Investigational Site

    Metropolitan Borough of Wirral, Merseyside, CH49 5PE

  • Pfizer Investigational Site

    Newcastle upon Tyne, NE1 4LP

  • Pfizer Investigational Site

    Solihull, West Midlands, B91 2JL

Other trials in United Kingdom

Colombia3 sites
  • Pfizer Investigational Site

    Barranquilla, Atlántico, 0000

  • Pfizer Investigational Site

    Bogota, Cundinamarca

  • Pfizer Investigational Site

    Bucaramanga, Santander Department

Other trials in Colombia

Finland3 sites
  • Pfizer Investigational Site

    Helsinki, 00120

  • Pfizer Investigational Site

    Hyvinkää, 05800

  • Pfizer Investigational Site

    Tampere, 33520

Other trials in Finland

Russia3 sites
  • Pfizer Investigational Site

    Moscow, 115093

  • Pfizer Investigational Site

    Moscow, 115446

  • Pfizer Investigational Site

    Petrozavodsk, 185019

Other trials in Russia

Sweden3 sites
  • Pfizer Investigational Site

    Falun, 791 82

  • Pfizer Investigational Site

    Gothenburg, 413 46

  • Pfizer Investigational Site

    Uppsala, 751 85

Other trials in Sweden

Thailand3 sites
  • Pfizer Investigational Site

    Amphoe Muang, Chiang Mai, 50200

  • Pfizer Investigational Site

    Muang District, Khonkaen, 40002

  • Pfizer Investigational Site

    Rajathevee, Bangkok, 10400

Other trials in Thailand

Croatia2 sites
  • Pfizer Investigational Site

    Opatija, 51410

  • Pfizer Investigational Site

    Zagreb, 10000

Other trials in Croatia

Venezuela2 sites
  • Pfizer Investigational Site

    Caracas, DC/ Municipio Libertados, 1040-A

  • Pfizer Investigational Site

    Caracas, Distrito Federal, 1010

Other trials in Venezuela

Denmark1 site
  • Pfizer Investigational Site

    Frederiksberg, 2000

Other trials in Denmark

Greece1 site
  • Pfizer Investigational Site

    Maroussi Athens, 15126

Other trials in Greece

About this study

Official title: Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS

This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.

Being tested
CP-690,550, Placebo
Keywords
Arthritis, Rheumatoid, Antirheumatic Agents, Clinical Trial
Medical subject headings
Arthritis, Rheumatoid, Arthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CP-690,550Drug

    Film coated tablet, 5 mg PO BID, 1 year

  • CP-690,550Drug

    Film coated tablet, 10 mg PO BID, 1 year

  • PlaceboDrug

    Film coated tablet, 1 tablet PO BID, 3-6 months

  • PlaceboDrug

    Film coated tablet, 1 tablet PO BID, 3-6 months

Study groups in NCT00856544
Study groupRoleWhat they receive
Active 5 mgExperimentalNot described
Receives: Drug: CP-690,550
Active 10 mgExperimentalNot described
Receives: Drug: CP-690,550
Placebo Sequence 1Placebo comparatorPlacebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
Receives: Drug: Placebo
Placebo Sequence 2Placebo comparatorPlacebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6

    ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Month 6

  2. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities:dress/groom;arise;eat; walk;reach;grip; hygiene;common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty;1=some difficulty;2=much difficulty;3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3:0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.

    Measured: Baseline, Month 3

  3. Percentage of Participants Achieving Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])Less Than 2.6 at Month 6

    DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, erythrocyte sedimentation rate (ESR) (millimeters/hour[mm/hour]) and patient's global assessment (PtGA) of disease activity(participant rated arthritis activity assessment). Total score range:0-9.4, higher score=more disease activity. DAS28-4 (ESR) less than or equal to (<=)3.2 implied low disease activity, greater than (>)3.2 to 5.1 implied moderate to high disease activity, less than (<)2.6=remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.

    Measured: Month 6

Secondary outcomes (42)
  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Week 2, Month 1, 2, 3, 4.5 and 6

    ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Week 2, Month 1, 2, 3, 4.5, 6

  2. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 9 and 12

    ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 9, 12

  3. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Week 2, Month 1, 2, 3, 4.5 and 6

    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Week 2, Month 1, 2, 3, 4.5, 6

  4. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 9 and 12

    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 9, 12

  5. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Week 2, Month 1, 2, 3, 4.5 and 6

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Week 2, Month 1, 2, 3, 4.5, 6

  6. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 9 and 12

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

    Measured: Month 9, 12

  7. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6

    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Week 2, Month 1, 2, 3, 4.5, 6

  8. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12

    DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Month 9, 12

  9. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 3 and 6

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 3, 6

  10. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 12

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Month 12

  11. Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])

    DAS28-4 (CRP) was calculated from SJC and TJC using the 28 joints count, CRP [mg/L] and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 [CRP] <=3.2 implied low disease activity, DAS28-4 [CRP] >3.2 to 5.1 implied moderate to high disease activity and DAS28 <2.6 implied remission.

    Measured: Baseline, Week 2, Month 1, 2, 3, 4.5, 6, 9, 12

  12. Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])

    DAS28-3 (ESR) was calculated from the number of SJC and TJC using the 28 joints count and ESR (mm/hr). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.

    Measured: Baseline, Month 3, 6, 12

  13. Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

    Measured: Baseline, Week 2, Month 1, 2, 3, 4.5, 6

  14. Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 9 and 12

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

    Measured: Month 9, Month 12

  15. Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6

    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Baseline, Week 2, Month 1, 2, 3, 4.5, 6

  16. Patient Assessment of Arthritis Pain at Month 9 and 12

    Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Month 9, 12

  17. Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.

    Measured: Baseline, Week 2, Month 1, 2, 3, 4.5, 6

  18. Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.

    Measured: Month 9, 12

  19. Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Baseline, Week 2, Month 1, 2, 3, 4.5, 6

  20. Physician Global Assessment (PGA) of Arthritis at Month 9 and 12

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Month 9, 12

  21. 36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Baseline, Month 1, 3, 6

  22. 36-Item Short-Form Health Survey (SF-36) at Month 9 and 12

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Month 9, 12

  23. Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.

    Measured: Baseline, Month 1, 3, 6

  24. Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

    Measured: Baseline, Month 1, 3, 6

  25. Medical Outcome Study (MOS) Sleep Scale at Month 12

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.

    Measured: Month 12

  26. Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

    Measured: Month 12

  27. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline, Month 1, 3, and 6

    FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Baseline, Month 1, 3, 6

  28. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 12

    FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Month 12

  29. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline, Month 3 and 6

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Month 3, 6

  30. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 12

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Month 12

  31. Work Limitations Questionnaire (WLQ) Score at Baseline, Month 3 and 6

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: time management scale (5-items); physical demands scale (6-item); mental-interpersonal demands Scale (9-items); output demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work loss index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).

    Measured: Baseline, Month 3, 6

  32. Work Limitations Questionnaire (WLQ) Score at Month 12

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: time management scale (5-items); physical demands scale (6-item); mental-interpersonal demands scale (9-items); output demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work loss index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).

    Measured: Month 12

  33. Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6

    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor, non-medical practitioner, nursing home, hospital, surgery, emergency room(ER) treatment, diagnostic tests, over-night stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status, willingness to work, work disability due to RA, sick leave,part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.

    Measured: Baseline, Month 3, 6

  34. Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12

    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.

    Measured: Month 12

  35. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Baseline, Month 3, 6

  36. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Month 12

  37. Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Baseline, Month 3, 6

  38. Number of Days as Assessed Using RA-HCRU at Month 12

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Month 12

  39. Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

    Measured: Baseline, Month 3, 6

  40. Number of Hours Per Day as Assessed RA-HCRU at Month 12

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

    Measured: Month 12

  41. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6

    Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

    Measured: Baseline, Month 3, 6

  42. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12

    Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

    Measured: Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionJan 2011
  4. Study completionJan 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
795 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00856544
Sponsor's protocol ID
A3921046
Status last verified
Dec 2012
First submitted
3 Mar 2009
Last updated
10 Jan 2013
Data monitoring committee
Yes

Publications

  • Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.

    PubMed 42888330
  • Strand V, Schulze-Koops H, Al-Emadi S, Kinch CD, Gruben D, Germino R, Connell CA, Mysler E. Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. BMJ Open. 2025 Dec 24;15(12):e082366. doi: 10.1136/bmjopen-2023-082366.

    PubMed 41448717
  • Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.

    PubMed 39192350
  • Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.

    PubMed 38958913
  • Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials. Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.

    PubMed 37925660
  • Tesser J, Gul A, Olech E, Oelke K, Lukic T, Kwok K, Ebrahim A. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials. Arthritis Res Ther. 2023 Nov 2;25(1):214. doi: 10.1186/s13075-023-03154-z.

    PubMed 37919780
  • Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.

    PubMed 37453736
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.

    PubMed 36601090
  • Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.

    PubMed 36600185
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.

    PubMed 35577477
  • Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Arthritis Res Ther. 2022 Apr 5;24(1):83. doi: 10.1186/s13075-022-02724-x.

    PubMed 35382883
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.

    PubMed 34921355

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 133 sites in 20 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 133 sites in United States, China, Australia, Germany, Slovakia and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 (time frame: Month 6). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00856544, which also lists 28 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2013; AzTrials last refreshed its copy on 1 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in